AnaptysBio (ANAB) CMO Paul Lizzul Receives 16,667-Share Award

What Happened Paul F. Lizzul, Chief Medical Officer of AnaptysBio, was granted 16,667 performance-based restricted stock units (PSUs) on March 12, 2026. The award is reported as a derivative acquisition (A) at $0.00 per share (no cash paid). The PSUs were certified as earned by the Compensation Committee on March 12, 2026.

Key Details

• Transaction date: March 12, 2026; Filing date (Form 4): August 7, 2026 (late filing).
• Transaction type/code: Award (A) — 16,667 PSUs acquired; price reported $0.00 (derivative grant).
• Value: Reported acquisition value $0 (award of PSUs rather than a cash purchase).
• Vesting/settlement: Each PSU converts to one share; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to continued service.
• Footnotes: PSUs were earned upon achievement of performance criteria certified by the Compensation Committee.
• Shares owned after transaction: Not disclosed in this Form 4.

Context This was a compensation award (performance-based RSUs), not an open-market purchase or sale. PSUs are conditional rights to receive common stock upon vesting and typically reflect compensation tied to performance goals; they do not represent immediate tradable shares. The Form 4 was filed several months after the March 12, 2026 certification (filed Aug 7, 2026), which is a late filing and may warrant attention from investors tracking timely insider activity.